CN102365288A - 普拉格雷氢溴酸盐的晶体 - Google Patents

普拉格雷氢溴酸盐的晶体 Download PDF

Info

Publication number
CN102365288A
CN102365288A CN2010800142017A CN201080014201A CN102365288A CN 102365288 A CN102365288 A CN 102365288A CN 2010800142017 A CN2010800142017 A CN 2010800142017A CN 201080014201 A CN201080014201 A CN 201080014201A CN 102365288 A CN102365288 A CN 102365288A
Authority
CN
China
Prior art keywords
crystal
crystals
composition
acetic acid
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2010800142017A
Other languages
English (en)
Other versions
CN102365288B (zh
Inventor
袁哲东
程兴栋
杨玉雷
童玲
俞雄
张来芳
周文亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Dude Pharmaceutical Technology Co ltd
Shanghai Institute of Pharmaceutical Industry
Original Assignee
Shanghai Dude Pharmaceutical Technology Co ltd
Shanghai Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Dude Pharmaceutical Technology Co ltd, Shanghai Institute of Pharmaceutical Industry filed Critical Shanghai Dude Pharmaceutical Technology Co ltd
Priority to CN201080014201.7A priority Critical patent/CN102365288B/zh
Publication of CN102365288A publication Critical patent/CN102365288A/zh
Application granted granted Critical
Publication of CN102365288B publication Critical patent/CN102365288B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

本申请公开了2-乙酰氧基-5-(α-环丙基羰基-2-氟苄基)-4，5，6，7-四氢噻吩并[3，2-c]吡啶氢溴酸盐的晶体，以及含该晶体的晶体组合物和药物组合物以及其用途。本申请公开的普拉格雷氢溴酸盐晶体具有很好的稳定性及溶解性。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201080014201.7A 2009-03-31 2010-03-31 普拉格雷氢溴酸盐的晶体 Expired - Fee Related CN102365288B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201080014201.7A CN102365288B (zh) 2009-03-31 2010-03-31 普拉格雷氢溴酸盐的晶体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200910030050.3 2009-03-31
CN200910030050 2009-03-31
CN201080014201.7A CN102365288B (zh) 2009-03-31 2010-03-31 普拉格雷氢溴酸盐的晶体
PCT/CN2010/071464 WO2010111951A1 (zh) 2009-03-31 2010-03-31 普拉格雷氢溴酸盐的晶体

Publications (2)

Publication Number Publication Date
CN102365288A true CN102365288A (zh) 2012-02-29
CN102365288B CN102365288B (zh) 2014-04-09

Family

ID=42827491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080014201.7A Expired - Fee Related CN102365288B (zh) 2009-03-31 2010-03-31 普拉格雷氢溴酸盐的晶体

Country Status (7)

Country Link
US (1) US8772488B2 (zh)
EP (1) EP2415774B1 (zh)
JP (1) JP5501438B2 (zh)
CN (1) CN102365288B (zh)
CA (1) CA2757189C (zh)
RU (1) RU2484094C1 (zh)
WO (1) WO2010111951A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5501438B2 (ja) 2009-03-31 2014-05-21 上海医薬工業研究院 プラスグレル臭化水素酸塩の結晶
KR20140110096A (ko) 2010-04-08 2014-09-16 테바 파마슈티컬 인더스트리즈 리미티드 프라수그렐 염의 결정형
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000418A2 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
CN101255169A (zh) * 2008-03-26 2008-09-03 山东大学 普拉格雷盐及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20100105763A (ko) * 2000-07-06 2010-09-29 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP5501438B2 (ja) 2009-03-31 2014-05-21 上海医薬工業研究院 プラスグレル臭化水素酸塩の結晶
WO2011004392A1 (en) 2009-07-06 2011-01-13 Glenmark Generics Limited Crystalline form of prasugrel hydrobromide, preparation and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000418A2 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
CN101255169A (zh) * 2008-03-26 2008-09-03 山东大学 普拉格雷盐及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《国际药学研究杂志》 20081031 荆亚萍,等 新一代血小板抑制剂--普拉格雷 第373-376页 1-16 第35卷, 第5期 *
荆亚萍,等: "新一代血小板抑制剂——普拉格雷", 《国际药学研究杂志》 *

Also Published As

Publication number Publication date
EP2415774A1 (en) 2012-02-08
EP2415774B1 (en) 2014-07-09
US8772488B2 (en) 2014-07-08
CA2757189A1 (en) 2010-10-07
JP5501438B2 (ja) 2014-05-21
CA2757189C (en) 2016-02-16
RU2484094C1 (ru) 2013-06-10
EP2415774A4 (en) 2013-01-02
CN102365288B (zh) 2014-04-09
WO2010111951A1 (zh) 2010-10-07
US20120095035A1 (en) 2012-04-19
JP2012522023A (ja) 2012-09-20

Similar Documents

Publication Publication Date Title
CA2900322C (en) Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
EP2112155B1 (en) Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
HU226766B1 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
CN102365288A (zh) 普拉格雷氢溴酸盐的晶体
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
JP2022540818A (ja) Ｒｂｐ４阻害剤の製剤および使用の方法
CN114163453A (zh) 一种洛普替尼晶型及其制备方法
RU2256666C2 (ru) Кристаллические формы производного пиримидинового нуклеозида (варианты), фармацевтическая композиция, способ профилактики и лечения опухолевых заболеваний и применение кристаллической формы
EP2386560A1 (en) Crystalline clopidogrel naphthalenesulfonate hydrate, method for preparing same and pharmaceutical composition containing same
JP5666464B2 (ja) 新規化合物
EP1163241B1 (en) Zolpidem salts
WO2016197980A1 (zh) 一种黄芩苷a晶型、其制备方法及其应用
CN112047990B (zh) 阿糖胞苷前药mb07133晶型及其应用
EP0864572B1 (en) Crystal of hydrate and process for preparation thereof
JP4597463B2 (ja) ５−アミノサリチル酸のアゾ誘導体の新規な塩
CN118146216A (zh) Ceralasertib的盐的多晶型物及其制备方法
CN116354956A (zh) 维利西呱晶型及其制备方法
EP1523978A2 (en) Crystalline forms of pravastatin sodium
JP2002540110A (ja) トリアゾロピロミジノール化合物及びその塩
KR20080106232A (ko) 베시피르딘 클로하이드레이트의 결정형, 그 제조 방법 및 용도
MX2011009395A (es) Formas cristalinas de pemetrexed y proceso de obtencion.
PL195489B1 (pl) Forma krystaliczna (-)-(S)-bromofosfamidu, sposób jej otrzymywania i zawierająca ją stała doustna postać dawkowania

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409

Termination date: 20210331

CF01 Termination of patent right due to non-payment of annual fee